EUVIMEDAvasta EUVIMED
CrossrefInfokaart

Extracellular galectin-3 preferentially through CD44 and PD-1 binds activated T cells and marks memory-phenotype T cell subsets

Amal Abouda, Emmanuel T. Alimo, Ako Azimi, AmirAli Bigleri, Amirhossein Rahmati, Shima Shahbaz, Shokrollah Elahi

Frontiers in Immunology · 2026-11-04 · 17

DOI: 10.3389/fimmu.2026.1940192 ↗
AbstraktBibliograafilised andmed

Abstrakt

Background Galectin-3 (Gal-3) is a multifunctional β-galactoside-binding lectin implicated in immune regulation, yet its association with T cell phenotypes under physiological and inflammatory conditions remains incompletely defined. Methods We investigated Gal-3 expression and binding on murine and human T cells across developmental stages, tissues, sex, genetic background, circadian time, and inflammatory disease settings. Results In mice, Gal-3-associated CD4 + and CD8 + T cells were dynamically regulated by age, anatomical location, strain, sex, and circadian rhythm. Gal-3 + T cells displayed increased activation markers, enhanced TCR-associated signaling molecules, elevated cytolytic mediators, increased proliferation, and greater apoptosis. Gal-3 + T cells were enriched within central and effector memory compartments and expressed higher levels of co-inhibitory receptors, including PD-1, with ImageStream analysis confirming Gal-3 co-expressed with PD-1. Recombinant Gal-3 preferentially bound activated, but not resting T cells, and associated with CD44 and CD3, suggesting activation-dependent acquisition of extracellular Gal-3. Re-analysis of human thymocyte and Long COVID single-cell RNA-seq datasets further supported an association between LGALS3 expression and activated/exhausted T cell states. Finally, intracellular staining indicated that T cells are unlikely to be a major source of Gal-3. Conclusion Our findings identify Gal-3 as a context-dependent marker and potential regulator of activated, antigen-experienced T cells, which promotes T cell apoptosis.

Teadmised, mis sobivad teie tööga.

Tasuta alustamisest ja isiklikust kirjanduse otsingust kuni täieliku Research Suite’ini.

Vaata pakette →

Kas kõik kirjastajate täistekstid on kaasatud?

Ei. Bibliograafilised kirjed, kokkuvõtted ja täistekstid on erinevad sisud. See, kas täistekst on saadaval, sõltub allikast, Open Accessist ja teie olemasolevatest litsentsidest. EUVIMED-i pakett ei asenda täiendavaid kirjastajaõigusi.

Vaata pakette →